A record to read carefully

Bremelanotide: evidence profile

Approved product · Randomized evidence

Status recorded · Page published

Read the product, route and approval scope together. A category label does not replace those details. Use the exercise to prepare questions, not to choose a treatment.

Evidence record

Product and route
Subcutaneous injection.
Approval scope
Vyleesi: eligible premenopausal women with distressing acquired generalized low-desire disorder.
Mechanism
Melanocortin-receptor agonist.
Evidence
Randomized trials.
Limits
Exclude medical, relationship and drug causes; not performance enhancement.
Safety context
Uncontrolled hypertension or known cardiovascular disease: contraindicated.

Try this while reading

When comparing two summaries about bremelanotide, check what each uses as its starting point. One sentence might discuss change from an earlier visit, while another might compare groups at a later visit; treat this as a possibility to check, not something to assume about the report. Write the two comparison descriptions beneath the summaries before looking at which sounds more encouraging. Include the dates and whose measurements appear on each side. If you cannot complete a description, find the relevant table note. Your eventual comparison should keep those reference points visible instead of merging different questions into one account of progress.

Questions to keep

  1. Does each summary compare visits, groups, or another stated reference?
  2. Whose measurements and which dates belong on each side?
  3. What table note would fill the missing part of my comparison description?

Sources to open

Checked dates belong to the linked records, rather than to this page's publication.

  1. VYLEESI — NLM; checked
  2. Kingsberg trials — PubMed; checked